Compare Fresenius Medical Care AG & Co. KGaA (FMS) vs DaVita Inc. (DVA) vs The Oncology Institute, Inc. (TOI) vs Concord Medical Services Holdings Limited (CCM) Stock

Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus DaVita Inc. at 17.2x. On forward P/E, Concord Medical Services Holdings Limited is actually cheaper at 0.9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1.52x versus Fresenius Medical Care AG & Co. KGaA's 1.94x — a reasonable growth-adjusted valuation.

Over the past 5 years, DaVita Inc. (DVA) delivered a total return of +52.0%, compared to -90.1% for Concord Medical Services Holdings Limited (CCM). A $10,000 investment in DVA five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: DVA returned +136.9% versus CCM's -92.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.25β versus The Oncology Institute, Inc.'s 1.56β — meaning TOI is approximately 526% more volatile than CCM relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 34% for The Oncology Institute, Inc. — giving it more financial flexibility in a downturn.

DaVita Inc. (DVA) is the more profitable company, earning 5.5% net margin versus -80.3% for Concord Medical Services Holdings Limited — meaning it keeps 5.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DVA leads at 14.7% versus -138.6% for CCM. At the gross margin level — before operating expenses — DVA leads at 27.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1.52x versus Fresenius Medical Care AG & Co. KGaA's 1.94x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Concord Medical Services Holdings Limited (CCM) trades at 0.9x forward P/E versus 11.0x for DaVita Inc. — 10.1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 73.0% to $5.00.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DaVita Inc. (DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.35), +136.9% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1.56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DVA: +136.9%, TOI: -70.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: FMS is a mid-cap deep-value stock; DVA is a mid-cap deep-value stock; TOI is a small-cap quality compounder stock; CCM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.